Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Automated delineation of putative non-contrast-enhancing tumor in glioblastoma: Prognostic insights

  • Gómez-Mahiques, María
  • Garcia-Gomez, Juan M
  • Montosa-Micó, Víctor
  • López-Mateu, Carlos
  • Gil-Terrón-Rodríguez, Francisco Javier|||0000-0002-3536-6462
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Svensson, SF
  • Mireles, Eduardo Erasmo Mendoza
  • Vik-Mo, Einar Osland
  • Emblem, Kyrre E.
  • Balana-Quintero, Carme
  • Puig, Josep
  • Alenda, Cristina
  • Martinez-Saez, Elena
  • Martinez-Ricarte, Fran
  • Quiros-Marti, Marta
  • Quilis-Quesada, Vicent
[EN] Background Precise delineation of non-contrast-enhancing tumor (nCET) in glioblastoma (GB) is critical for maximal safe resection, yet routine imaging cannot reliably separate infiltrative tumor from vasogenic edema. The aim of this study was to develop and validate an automated method to identify peritumoral subregions compatible with nCET and assess its prognostic value.Methods Pre-operative T2-weighted and FLAIR MRI from 940 patients with newly diagnosed GB in four multicenter cohorts were analyzed. A deep-learning model segmented enhancing tumor, edema and necrosis; a non-local, spatially varying finite mixture model was applied to identify edema subregions characterized by relatively lower FLAIR hyperintensity, hypothesized to reflect nCET-related tissue. The ratio of these subregions to total edema volume defined the T2/FLAIR Heterogeneity Index (TFHI). Associations between TFHI and overall survival (OS) were examined with Kaplan-Meier curves and multivariable Cox regression.Results Higher TFHI values stratified patients with shorter OS. In the NCT03439332, TFHI above the optimal threshold was associated with a twofold increased hazard of death (hazard ratio [HR] 2.07, 95 % confidence interval 1.33-3.21; P = .0013) and a reduction in median survival of 98 days. Significant, though smaller, prognostic effects were confirmed in GLIOCAT & BraTS (HR= 1.37; P = .047), OUS (HR = 1.37; P = .0032) and pooled analysis (HR= 1.26; P = .0008). TFHI remained an independent predictor after adjustment for age, extent of resection and MGMT methylation.Conclusions We present a reproducible, server-hosted tool for automated identification of imaging-defined, putative nCET-related peritumoral subregions and TFHI biomarker extraction that enables independent prognostic stratification. This approach provides a quantitative framework for studying peritumoral heterogeneity in GB., Spanish Ministry of Science, Innovation and Universities (FPU23/02431); European Research Council (758657-ImPRESS); Helse Sor-& Oslash;st Regional Health Authority (2021057, 2017073); Research Council of Norway (325971, 261984, 303249, 32543); Fundacio La Marato de TV3 (665/C/2013); Instituto de Salud Carlos III (PI18/01062); Generalitat Valenciana (INVEST/2022/298, CIAICO/2022/064); Agencia Valenciana de la Innovacion (INNEST/2022/87); Universitat Politecnica de Valencia (PAID-01-24); This work was funded by Grant PID2021-127110OA-I00 (PROGRESS) funded by MCIN/AEI/10.13039/501100011033 and by ERDF. In addition, Project ECHIDNA (PID2024-156848OB-I00) and LAB2OR (PDC2025-165365-I00) funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU. Funding for open access charge: CRUE-Universitat Politecnica de Valencia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Biomechanical mapping of tumor growth: A novel method to quantify glioma infiltration and mass effect

  • López-Mateu, Carlos
  • Gómez-Mahiques, María
  • Montosa-Micó, Víctor
  • Gil-Terrón-Rodríguez, Francisco Javier|||0000-0002-3536-6462
  • Garcia-Gomez, Juan M
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Sederevicius, Donatas
  • Emblem, Kyrre E.
[EN] Background: Glioblastoma (GBM) growth can alter surrounding brain tissue through location-dependent physiological changes. Two main growth phenotypes¿(I) infiltrative, characterized by diffuse invasion with minimal mass effect, and (II) proliferative, characterized by pronounced tissue compression¿are recognized, but their quantitative characterization and prognostic impact remain poorly explored. Purpose: To develop and validate a novel MRI-based biomarker, the Dynamic Infiltration Rate (DIR), that quantitatively assesses the balance between tumor volume expansion and peritumoral compression, and to evaluate its prognostic ability for stratifying patients based on overall survival (OS). Methods: The DIR was defined as the ratio between tumor-volume enlargement and mass-effect-induced peritumoral compression. Technical validation was conducted using synthetic datasets with known ground truth spanning realistic infiltrative-proliferative spectra. Clinically, patients were dichotomized into high- and low-infiltration groups using a threshold optimized by maximizing the log-rank statistic for OS. Prognostic evaluation included multivariate Cox regression adjusted for age, sex, and MGMT methylation status. Results: The synthetic dataset validation demonstrated high concordance with ground truth (R² = 0.89). Clinical evaluation indicated significantly improved OS in the low DIR group (median = 35.2 weeks) compared to the high DIR group (median = 16.0 weeks; p = 0.0001). DIR effectively stratified patients based on survival (log-rank p < 0.001, HR = 2.49) and remained an independent prognostic factor on multivariate analysis (HR = 1.45, 95% CI 1.07¿1.85; p = 0.0159). Conclusions: The DIR is a novel and robust quantitative MRI biomarker capable of distinguishing between proliferative and infiltrative GBM phenotypes, independently predicting OS. Early phenotype identification could facilitate personalized treatment strategies and individualized follow-up scheduling., MCIN/AEI (Ministerio de Ciencia, Innovación y Universidades / Agencia Estatal de Investigación), Grant/Award Numbers: PID2024156848OB-I00, PID2021-127110OA-I00, PDC2025-165365-I00, FPU23/02431; Generalitat Valenciana, Grant/Award Numbers: INVEST/2022/298 (ProgramaINVESTIGO), CIAICO/2022/064(Lalaby-Glio), INNEST/2022/87(SINUÉ); European Research Council, Grant/Award Numbers: 758657-ImPRESS, 101213953-CHRONOS; Helse Sør-Øst RHF, Grant/Award Numbers: 2021057, 2017073, 2023050; Research Council of Norway, Grant/Award Numbers: 325971, 261984, 303249, 32543, 356066; Norwegian Cancer Society, Grant/Award Number: 309012 - SAFARI; Universitat Politècnica de València, Grant/Award Number: PAID-01-24(Subprogram1)